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To investigate the effect of choline alfoscerate (CA) on hearing amplification in patients
with age related hearing loss, we performed a prospective case-control observational
study from March 2016 to September 2020. We assessed patients with bilateral word
recognition score (WRS) <50% using monosyllabic words. The patients were 65–
85 years old, without any history of dementia, Alzheimer’s disease, parkinsonism, or
depression. After enrollment, all patients started using hearing aids (HA). The CA group
received a daily dose of 800 mg CA for 11 months. We performed between-group
comparisons of audiological data, including pure tone audiometry, WRS, HA fitting data
obtained using real-ear measurement (REM), and the Abbreviated Profile of Hearing Aid
benefit scores after treatment. After CA administration, the WRS improved significantly
in the CA group (4.2 ± 8.3%), but deteriorated in the control group (−0.6 ± 8.1%,
p = 0.035). However, there was no significant between-group difference in the change
in pure tone thresholds and aided speech intelligibility index calculated from REM.
These findings suggest that the difference in WRS was relevant to central speech
understanding rather than peripheral audibility. Therefore, administering oral CA could
effectively enrich listening comprehension in older HA users.
Keywords: age-related hearing loss, hearing aids, choline alfoscerate, abbreviated profile of hearing aid benefit,
listening comprehension
INTRODUCTION
Age-related hearing loss (ARHL) or presbycusis is one of the most common neurodegenerative
ailments in developed countries. It causes distorted communication and also impedes older
adults from participating in psychosocial activities due to social isolation, loss of self-esteem, and
depression (Disease et al., 2016). Moreover, hearing impairment is considered a modifiable risk
factor for dementia prevention (Livingston et al., 2020). As there is no cure for presbycusis, hearing
aids (HAs) have been strongly recommended to allow enriched audibility, ease of communication
(EC), and cognitive decline prevention in older adults (Livingston et al., 2020). In the aging
population, hearing difficulty is attributed to peripheral hearing loss associated with cochlear
degeneration; central auditory processing deficit from the cochlear nucleus to the primary auditory
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cortex; or cognitive decline in various domains, including
executive function, language memory, situational and semantic
long-term memory, and psychomotor processing (Humes et al.,
2012; Ronnberg et al., 2013; Panza et al., 2015). Although several
studies have reported cognitive-sensory interactions, including
the association between working memory and speech perception
through diverse tests, multifactorial conditions including age
and/or auditory system pathology may affect ARHL. Moreover,
there is no evidence regarding the apparent direction of causality
(Akeroyd, 2008; Humes et al., 2012; Murphy et al., 2018).
From an audiological perspective, hearing loss, which is
clinically distinctive for high-frequency hearing loss and the roll-
over phenomenon, results in impaired hearing sensitivity and
recognition, particularly with respect to noise, central sound
processing, and sound localization (Gates and Mills, 2005).
Pathologic and neuroanatomical changes in ARHL include cell
degeneration in the cochlea and auditory nerve, as well as cortical
neuroplasticity changes, including decreased gray matter volume
in the auditory cortex, anterior cingulate, and superior and
medial frontal gyri (Gates and Mills, 2005; Husain et al., 2011;
Eckert et al., 2012). Furthermore, compared with participants
with normal hearing, patients with ARHL present with a greater
decrease in spontaneous activity and local connectivity in the
parahippocampal gyri and hippocampus on functional magnetic
resonance imaging (MRI) (Chen et al., 2018, 2020). Therefore,
improving audibility through acoustic amplification or cochlear
implantation with prolonged auditory deprivation allows limited
gains in speech intelligibility among older adults with ARHL
(Lazard et al., 2012).
Choline alfoscerate (CA, L-alpha-glycerylphosphorylcholine),
a semisynthetic derivative of phosphatidylcholine, is a common
acetylcholine precursor in the brain (Amenta et al., 2001). CA
reportedly enhances memory and cognition in patients with
Alzheimer’s disease (AD) and stroke (Lee S.H. et al., 2017).
Moreover, its neuroprotective effects have been reported in
experimental models of AD, stroke, and pilocarpine-induced
seizures (Lee S.H. et al., 2017; Catanesi et al., 2020). For
these neurodegenerative diseases, the use of nutraceuticals for
cholinergic neurotransmission could be a treatment option;
further, several studies have reported the effect of CA on cognitive
improvement (De Jesus Moreno Moreno, 2003; Lee S.H. et al.,
2017). Considering cholinergic signaling in thalamocortical
neurons of the medial geniculate body (MGB), which play a core
role as major synaptic stations in central auditory processing, as
well as the association between ARHL and cognition decline, we
hypothesized that CA would contribute toward improving speech
recognition in patients with ARHL. We aimed to assess the effect




This study was approved by the Institutional Review Board (IRB)
of Severance Hospital (4-2017 1152) and conducted following
the principles of the Declaration of Helsinki. All research was
performed in accordance with relevant guidelines and regulations
from the IRB of Severance Hospital. All participants signed an
informed consent.
Prospective Study Design
We analyzed 640 patients who attended the Yonsei University
Health System Hearing Aids Clinic (YHC) between March 2016
and September 2020. The inclusion criteria were as follows: (1)
aged >65 and <85 years; (2) sensorineural hearing loss; (3)
<50% of the bilateral word recognition score (WRS) at the most
comfortable loudness level (MCL) with unaided ears; (4) received
newly prescribed HA from an otologist (JJ); (5) completion of
1-year follow-up; (6) HA fitting over three times within a year;
and (7) being a literate, native Korean speaker. The exclusion
criteria were as follows: (1) previous diagnosis of dementia,
AD, parkinsonism, and depression; (2) taking CA previously
prescribed by other clinicians; and (3) >90% compliance with
CA administration determined by assessing the remaining pills
at every visit. After 1 month of HA use, all patients received
information on the original indication for the use of CA and
its unknown effects on listening comprehension, and were asked
whether they agreed to take CA. Subsequently, the patients were
allocated to the CA or control group according to their decision.
By means of the inclusion and exclusion criteria, 606 patients
were excluded. Finally, 23 ears of 14 patients in the CA group and
34 ears of 20 patients in the control group were comprehensively
analyzed (Figure 1). The patients in the CA group took
medicine for 11 months, while they used HA. In contrast, the
patients in the control group only used HA. Consequently,
primary outcomes were evaluated 1 year after initial fitting
of HA.
Audiological Data
Audiological evaluation was performed as previously described
(Jung et al., 2016, 2018; Lee H.J. et al., 2017). Baseline hearing
sensitivity was measured using pure tone audiometry (PTA)
with insert earphones or supra-aural headphones in a double-
walled sound-treated booth by experienced audiologists. The
aided sound-field threshold was measured with the patient
sitting 1 meter away from two loudspeakers at a 45◦ angle. The
average threshold (PTA4) was calculated using the thresholds
at 500, 1000, 2000, and 4000 Hz; moreover, we calculated the
average threshold of high frequencies (PTA3) at 1000, 2000,
and 4000 Hz. Baseline and aided word recognition tests in a
quiet environment were performed under similar conditions
as PTA. We measured the WRS (%) at the MCL using
50 monosyllabic words from Hahm’s list, which comprised
phonetically balanced Korean standard words (Han and Park,
1981). We defined MCL as the hearing level at which speaking
was most comfortably heard. Non-tested ears were masked using
a calibrated headphone (TDH-39).
HA Fitting Data
The digital, wide dynamic range compression HA and the
NAL-NL2 fitting program were prescribed for each patient
as previously described (Lee et al., 2020). Probe microphone
measurement was performed using the Otometrics Aurical
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FIGURE 1 | Flow chart of the case-control study for evaluating the effect of oral choline alfoscerate on speech detection and recognition in hearing aid users with
aging-related hearing loss.
FreeFit and Probe Microphone Measurements (PMM) module
(Taastrup, Denmark) with the International Speech Test Signal
(ISTS) at 55 dB (soft speech) and 65 dB sound pressure level (SPL)
(conversational level speech) using two external speakers for HA
verification. We calculated the proximity from the prescriptive
fitting target based on the baseline PTA to the rear-ear aided
response (REAR) using the root-mean-square error (RMSE) of









f = 500, 1000, 2000, and 4000Hz
RMSE changes between 1 month and 1 year after wearing
the HA were compared to confirm between-group uniformity
of HA fitting. There was no significant difference in the HA
output (REAR) between 1 month and 1 year after amplification
(Supplementary Table 1). Additionally, there were stable
changes in RMSE from the HA prescriptive targets at soft speech
and conversational level speech (Supplementary Figure 1).
Aided Speech Audibility
The speech intelligibility index (SII) is a calculated value for
determining whether sound energy sufficient for audibility is
transmitted based on each frequency, particularly weighting mid-
frequencies important for speech listening. The aided SII was
automatically calculated with the Aurical FreeFit/PMM system
using the ISTS as defined by ANSI S3.5-1997 (R2002) (American
National Standards Institute, 1997). This calculation was applied
to third-octave bands with consideration of the insertion gain at
65 dB SPL (conversational level speech).
Abbreviated Profile of Hearing Aid
Benefit
The Korean version of abbreviated profile of hearing aid benefit
(APHAB) was used to quantify hearing disability at 1 month and
1 year after HA fitting. The APHAB comprises 24 items scored in
four subscales: EC, reverberation (RV), background noise (BN),
and aversiveness of sound (AV) (Cox and Alexander, 1995). The
patients were asked questions regarding various situations of
hearing aid usage and frequency in daily life. Subscales of the
questionnaire were assessed separately, as EC, RV, and BN reflect
the listening experience under various environmental conditions,
while AV reflects the discomfort caused by environmental noise;
the global score, is an average of EC, RV, and BN, and AV scores
(Johnson et al., 2010).
HA Experience and Usage
Patients who had previously used HA before the HA fitting at
YHC were examined before HA prescription. We found that 30.4
and 29.4% of the ears in the CA and control group, respectively,
had previously used HA before the enrollment but were non-
users due to dissatisfaction. The daily hours of HA usage were
classified using self-reported data: <1, 1–4, 4–8, and 8–16 h at
every visit. Moreover, 91.3 and 88.2% of ears in the CA and
control group, respectively, were amplified for >4 h a day.
Statistical Analyses
All statistical analyses were completed using GraphPad Prism
8 (San Diego, CA, United States). Independent t-test, Mann–
Whitney U-test, and chi-square test were used for between-group
comparisons of quantitative variables, including audiometric
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data, HA fitting data, and questionnaires. The correlation
between changes in the WRS and SII was analyzed using
the Pearson correlation test. Statistical significance was set at
p < 0.05.
RESULTS
We analyzed 23 ears (14 patients) and 34 ears (20 patients)
in the CA and control groups, respectively. Patients in the
CA group received a daily oral dose of 800 mg CA for
11 months. Compliance with treatment was assessed at every
visit. Participant mean [SD] age in the CA and control groups
was 74.13 [6.12] and 75.21 [5.21] years, respectively (Table 1). In
both groups, various HA types were used according to receiver
preference, with the in-ear type being the most commonly used
type. Patients were followed up for 1 year with visits at the
1st, 3rd, 6, and 12th months from the initial day of HA fitting.
Additionally, aided PTA, WRS at the MCL, SII calculation from
rear-ear measurements and probe microphone measurement for
speech mapping were performed at each visit.
Initial Assessment
There was no significant difference between the CA group
and control group in the baseline pure tone average threshold
at 500, 1000, 2000, 4000 Hz (PTA4) (59.57 [8.97] and 60.26
[12.64] dB HL), PTA3 (average threshold at 1000, 2000, and
TABLE 1 | Patient characteristics.
CA group
(23 ears, n = 14)
Control group
(34 ears, n = 20)
p-Value
Age, mean [SD], year† 74.1 [6.1] 75.2 [5.2] 0.48
Sex‡ 0.22
Male 12 ears, n = 8 22 ears, n = 13
Female 11 ears, n = 6 12 ears, n = 7
HA experience, ears ‡ 7 (30.4%) 10 (29.4%) 0.93
HA side, n‡ >0.99
Unilateral 5 (35.7%) 6 (30%)
Bilateral 9 (64.3%) 14 (70%)
HA type, ears‡ 0.37
BTE 0 (0%) 2 (5.9%)
RIC 14 (60.9%) 18 (52.9%)
CIC 8 (34.8%) 14 (41.2%)
ITC 1 (4.3%) 0 (0%)
HA usage hours/day, ears‡ 0.37
1 ≤ < 4 2 (8.7%) 4 (11.8%)
4 ≤ < 8 11 (47.8%) 10 (29.4%)
8 ≤ < 16 10 (43.5%) 20 (58.8%)
Medical history, ears
Hypertension 8 (34.8%) 4 (11.8%)
Diabetes 6 (26.1%) 3 (8.8%)
Cardiovascular disease 4 (17.4%) 1 (2.9%)
BTE, behind the ear; CA, choline alfoscerate; CIC, completely in-canal; HA, hearing
aid; ITC, in the canal; RIC, receiver in canal.
† Independent t-test.
‡Chi-square test.
4000 Hz) (62.61 [9.92] and 64.26 [12.60] dB HL), and WRS
at MCL (29.83 [12.56] and 34.35 [11.20] %) (p = 0.82, 0.60,
and 0.16, respectively) (Table 2 and Supplementary Figure 2A).
Supplementary Figure 2B presents the distribution of the
baseline WRS as a function of PTA3, which is the average
threshold of high frequencies (Yellin et al., 1989; Gates et al.,
2003). The dotted line was adopted from the report by Yellin et al.
(1989) representing the estimated norm of cochlear ARHL for
differentiation from retro-cochlear ARHL. There were 9 (39.1%)
and 4 (11.8%) ears in the CA and control groups, respectively,
beneath the estimated threshold of hearing loss possibly resulting
from the retro-cochlear lesion.
After 1 month of HA usage, there was no between-group
difference in the aided PTA4 as a frequency function (p = 0.20).
However, aided WRS at MCL was significantly higher in the
control group (49 [14.72] %) than in the CA group (38.26 [15.21]
%) (p = 0.01). Furthermore, although the number of control
ears was lower, aided SII was significantly higher in the control
group (39.29 ± 16.05%) than in the CA group (29.83 [12.56] %)
(p = 0.03). There was no significant between-group difference
in both the APHAB scores (Global and Aversiveness scores)
(Supplementary Figure 3, p = 0.34 and 0.65, respectively).
Changes of Audiological Outcome After
1-Year Usage of HA
After 1 year of HA usage, there was no significant difference
between the CA group and control group in aided PTA4
(47.61 [5.92] and 48.05[8.43] dB HL), aided WRS (42.43 [16.94]
and 48.41 [15.68] %), and aided SII (35.65 [13.59] and 37.64
[13.25] %) (p = 0.83, 0.18, and 0.59, respectively). Further,
there was no significant between-group difference in the APHAB
score (Table 2).
Regarding the 1-year changes in the aided WRS, compared
with the control group, the CA group revealed a trend
toward improvement (Figure 2A). Notably, after 1 year of CA
administration, the aided WRS had significantly improved (4.17
[8.29] %) in the CA group and deteriorated (−0.59 [8.07] %)
in the control group (Figure 2B, p = 0.035). Contrastingly,
there was no between-group difference in the change of aided
SII (Figure 2C, p = 0.11). There was no significant correlation
between changes in the WRS and SII (Figure 2D, CA group:
p = 0.93; control group: p = 0.66). This suggests that improved
speech intelligibility in the CA group is attributable to central
cognitive function, with respect to speech comprehension, rather
than peripheral audibility.
DISCUSSION
This study aimed to evaluate whether CA administration plays
an adjuvant role in amplification for auditory perception,
including audibility and speech discrimination, in older adults
who are HA users with a WRS of <50%. We analyzed several
audiological measurements—PTA4, WRS, SII, and APHAB
score—to determine the parameters affected by CA during
auditory processing. Change in the WRS was the only salient
auditory function index across a year. CA administration did
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not improve audibility reflected by SII; however, it significantly
improved speech discrimination. Therefore, we consider that CA
contributes to improved speech intelligibility, which is irrelevant
to peripheral audibility; rather, it involves the central cognitive
ability, including speech comprehension, which occurs in parts
other than the peripheral auditory organ.
Given the relatively low feasibility of amplification in
individuals with ARHL whose speech discrimination is <50%
(amplification had an insufficient benefit other than lip-reading
or noticing environmental sounds due to poor WRS), studies
TABLE 2 | Audiological evaluations.
CA group Control
group
Baseline 23 ears, n = 14 34 ears,
n = 20
p-Value†
PTA4, mean [SD], dBHL 59.6 [9.0] 60.3 [12.6] 0.82
PTA3, mean [SD], dBHL 62.6 [9.9] 64.3 [12.6] 0.60
WRS at MCL, mean [SD],
%
29.8 [12.6] 34.4 [11.2] 0.16
MCL, mean [SD], dBHL 79.5 [7.3] 81.0 [8.9] 0.50





50.4 [6.3] 47.4 [9.8] 0.20
Aided WRS at MCL,
mean [SD], %
38.3 [15.2] 49.0 [14.7] 0.01∗
Aided MCL, mean [SD],
dBHL
69.0 [3.9] 68.2 [4.8] 0.56
Aided SII at 65 dB SPL,
mean [SD], %
29.8 [12.6] 39.3 [16.0] 0.03∗
APHAB 12 ears, n = 7 28 ears,
n = 16
U-value‡ p-value‡





50 [8.25–62] 48 [29–78.5] 152 0.65





47.6 [5.9] 48.1 [8.4] 0.83
Aided WRS at MCL,
mean [SD], %
42.4 [16.9] 48.4 [15.7] 0.18
Aided MCL, mean [SD],
dBHL
67.7 [4.3] 66.8 [6.0] 0.53
Aided SII at 65dBSPL,
mean [SD], %
35.7 [13.6] 37.6 [13.2] 0.59
APHAB 17 ears, n = 10 26 ears,
n = 15
U-value‡ p-value‡






APHAB, abbreviated profile of hearing aid benefit; CA, choline alfoscerate; MCL,
most comfort loudness; PTA3, the average pure tone threshold at 1000, 2000, and
4000 Hz; PTA4, the average pure tone threshold at 500, 1000, 2000, and 4000 Hz;
SII, speech intelligibility index; WRS, Word Recognition Score.
† Independent t-test.
‡Mann–Whitney U-test.
on amplification in this context are scarce. Moreover, few
studies have reported the speech discrimination score and fitting
data in the older-adult population (Dillon, 2012; Kim et al.,
2020). Pedersen et al. reported a gradual decrease in the speech
discrimination score by 8−10% after 11 years in an older-adult
population in their 70s (Pedersen et al., 1991). Dubno (2015)
reported a similar tendency showing a gradual decline of speech
discrimination in older adults, which accelerated near the age of
75 to 80 years. This is consistent with our findings of a relative
decrease in the aided WRS in our control group.
ARHL results from several related deteriorations, including
peripheral and central auditory processing and cognition. The
primary, non-invasive step for addressing ARHL is amplification
to complement the peripheral auditory processing. HA use
may reduce the listening effort; however, in severe hearing
loss, it cannot normalize the temporal and frequency resolution
(Ronnberg et al., 2013). Furthermore, in cases of cochlear
dead region, off-frequency listening causes distorted sound and
impedes optimal amplification. Therefore, there is a need for an
effective supplementary strategy to improve aural rehabilitation.
However, fitting HAs and obtaining an audiological gain is
very challenging among patients with WRS <50%. Given the
negative correlation between satisfaction with HAs and the initial
WRS, there is a need to improve speech intelligibility and
audibility through HAs. Unfortunately, there remains no option
for improving speech intelligibility. Therefore, the CA effect
on WRS is very promising for improving satisfaction with and
decreasing the rejection rate of HAs.
Numerous studies have reported the role of the cholinergic
system in the brain; specifically, in memory and cognitive
function, which are significantly degraded in aging-related
dementia and AD (Davies and Maloney, 1976; Grothe et al.,
2014; Haam and Yakel, 2017). In these diseases, CA directly
increases cholinergic transmission as an acetylcholine precursor
in the hippocampus to ameliorate cognitive symptoms or exerts
neuroprotective effects by activating the neurotrophin survival
pathway (Ciriaco et al., 1992; Sigala et al., 1992; De Jesus Moreno
Moreno, 2003). Accordingly, several studies have examined
the relationship between ARHL and the cholinergic system.
Acetylcholine is an efferent neurotransmitter in the medial
olivocochlear nucleus that is secreted to outer hair cells (OHC)
for efferent inhibition. The resulting OHC hyperpolarization
allows discrimination of sounds in BN and separation of the
frequency resolution (Winslow and Sachs, 1988; Glowatzki and
Fuchs, 2000). Tang et al. (2014) reported a decrease in mRNA
and protein expression of the nicotinic acetylcholine receptor
(nAChR) subunit β2 in the spiral ganglion neurons of old
mice (24−32 months) compared with that in young adult mice
(2−3 months). Further, given the higher level of central auditory
processing, the MGB in the auditory thalamus codes, gates, and
relays auditory information to the auditory cortex (AC) and
limbic structures (Guillery et al., 1998; Richardson et al., 2020).
In rats, there is a conspicuous decrease in mRNA levels of nAChR
subunits with aging compared with other brain regions with the
highest expression levels reported in young rats (7–14 months of
age) (Ferrari et al., 1999). The MGB receives descending signals
from the AC (excitatory input) and the thalamic reticular nucleus
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FIGURE 2 | Changes in audiological outcomes at 1 year after HA use. (A) Aided WRS as a function of wearing duration. Although the control group showed a stable
aided WRS, the choline alfoscerate (CA) group showed a rising tendency in the WRS. (B) Changes in the aided WRS between 1 month and 1 year after HA wearing
at each group. Notably, following 1 year of CA administration, the aided WRS significantly improved in the CA group but deteriorated in the control group (p = 0.035).
(C) There was no significant between-group difference in the change in the aided SII between 1 month and 1 year after using HA (p = 0.110). (D) There was no
significant correlation between changes in the aided WRS and SII (the CA group: p = 0.930; the control group: p = 0.660).
(inhibitory input). Moreover, ascending signals from the inferior
colliculus (IC), both excitatory and inhibitory sensory inputs,
modulate the MGB. In thalamocortical neurons in the MGB,
acetylcholine has both presynaptic and postsynaptic functions.
Cholinergic input from the pedunculopontine tegmental nuclei
regulates MGB neuronal activity directly (via somatodendritic
AChR) or indirectly (via presynaptic AChR by GABA modulation
or glutamate release) (Richardson et al., 2020). Sottile et al.
reported that tectothalamic inhibitory projections from the
IC reached the MGB through presynaptic cholinergic input
and were affected by the aging-induced decrease in nAChR
activation in rats (Sottile et al., 2017b). Therefore, aging might
result in deteriorated signal-to-noise ratio and sound detection
(Sottile et al., 2017a). Additionally, aging may reduce nAChR
density in the MGB, which evokes postsynaptic excitation and
contributes to loss of speech comprehension in older adults
(Sottile et al., 2017b).
Moreover, cholinergic dysfunction affects the hippocampus
and modulates memory function (Haam and Yakel, 2017).
The hippocampus, which is the limbic system core and is
involved in memory formation and sensory processing including
auditory information (Diederen et al., 2010), is part of a
system for auditory working memory that maintains sounds
in memory (Kumar et al., 2016). Moreover, voxel-based MRI
analysis has revealed distinct hippocampal atrophy in older
adults with ARHL compared with those showing mild-to-normal
hearing (Aoki et al., 2020). Ruan et al. (2018) reported that
withdrawing the cholinergic input to neuropeptide neuroglia
from hippocampal cells, mainly under cholinergic regulation,
may be involved in the excitation-inhibition imbalance in the
central auditory system by affecting GABA release. Although
we did not elucidate the mechanism underlying CA-mediated
amelioration of deteriorated speech discrimination, CA could
supply acetylcholine as a choline donor in the hippocampus.
Moreover, we can speculate the benefit of CA in ARHL as a
supplementary rehabilitation.
This study has several limitations. First, to explore the effect
of CA on the entire auditory processing, using peripheral
auditory tests in a quiet environment is insufficient and further
experimental tools for verifying central auditory processing,
working memory, or long-term memory are required. Second,
the sample size was too small to make a definitive conclusion and
more extensive studies are warranted to confirm these findings.
Third, given that the study was not a randomized controlled
neither blinded study, individuals who agreed to participate
in the supplementary rehabilitation were more motivated and
cooperative, resulting in selection bias. Fourth, even though the
distribution of medical histories such as hypertension, diabetes,
and cardiovascular disease was inconsistent in two groups, we
could not reach their complete medical record. The severity of
the disease or the effect of other medication they were taking
could have affected their hearing progression. Fifth, the side effect
of CA has not yet been revealed in the clinical study dealing
with patients without cognitive disorders (Choi et al., 2020). Even
though all patients in this study have not complained unexpected
symptoms or signs, there is a possibility for unintended efficacy
on the cholinergic system for better or worse; the long-term use
of CA should be monitored with precaution.
In conclusion, to enrich the listening comprehension in older
adults with ARHL, it is necessary to increase audibility and to
improve other factors associated with central auditory processing
or cognition by using approaches from multiple perspectives. CA
could be an affordable therapeutic option for older adult patients
with ARHL showing poor WRS.
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